83 related articles for article (PubMed ID: 17687276)
1. Intravenous parecoxib rapidly leads to COX-2 inhibitory concentration of valdecoxib in the central nervous system.
Mehta V; Johnston A; Cheung R; Bello A; Langford RM
Clin Pharmacol Ther; 2008 Mar; 83(3):430-5. PubMed ID: 17687276
[TBL] [Abstract][Full Text] [Related]
2. Development of a population pharmacokinetic model for parecoxib and its active metabolite valdecoxib after parenteral parecoxib administration in children.
Hullett B; Salman S; O'Halloran SJ; Peirce D; Davies K; Ilett KF
Anesthesiology; 2012 May; 116(5):1124-33. PubMed ID: 22450476
[TBL] [Abstract][Full Text] [Related]
3. Transfer of parecoxib and its primary active metabolite valdecoxib via transitional breastmilk following intravenous parecoxib use after cesarean delivery: a comparison of naive pooled data analysis and nonlinear mixed-effects modeling.
Paech MJ; Salman S; Ilett KF; O'Halloran SJ; Muchatuta NA
Anesth Analg; 2012 Apr; 114(4):837-44. PubMed ID: 22344242
[TBL] [Abstract][Full Text] [Related]
4. Prostaglandin I2 release following mesenteric traction during abdominal surgery is mediated by cyclooxygenase-1.
Bucher M; Kees FK; Messmann B; Lunz D; Rath S; Zelenka M; Schlitt HJ; Hobbhahn J
Eur J Pharmacol; 2006 May; 536(3):296-300. PubMed ID: 16581062
[TBL] [Abstract][Full Text] [Related]
5. An effective dose of valdecoxib in experimental mouse models of pain.
Guo CX; Irwin MG; Cheung KM; Chan D
Methods Find Exp Clin Pharmacol; 2007; 29(6):383-8. PubMed ID: 17922065
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological separation between peripheral and central functions of cyclooxygenase-2 with CIAA, a novel cyclooxygenase-2 inhibitor.
Okumura T; Murata Y; Hizue M; Matsuura T; Naganeo R; Kanai Y; Murase A; Sakakibara A; Fujita I; Nakao K
Eur J Pharmacol; 2006 Jun; 539(1-2):125-30. PubMed ID: 16690052
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of intravenous and intramuscular parecoxib in healthy Beagles.
Giorgi M; Saccomanni G; Del Carlo S; Manera C; Lavy E
Vet J; 2012 Jul; 193(1):246-50. PubMed ID: 22130459
[TBL] [Abstract][Full Text] [Related]
8. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans.
Dembo G; Park SB; Kharasch ED
Anesthesiology; 2005 Feb; 102(2):409-15. PubMed ID: 15681959
[TBL] [Abstract][Full Text] [Related]
9. The pharmacokinetics and in vitro/ex vivo cyclooxygenase selectivity of parecoxib and its active metabolite valdecoxib in cats.
Kim TW; Vercelli C; Briganti A; Re G; Giorgi M
Vet J; 2014 Oct; 202(1):37-42. PubMed ID: 25135338
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular safety of the cyclooxygenase-2 selective inhibitors parecoxib and valdecoxib in the postoperative setting: an analysis of integrated data.
Schug SA; Joshi GP; Camu F; Pan S; Cheung R
Anesth Analg; 2009 Jan; 108(1):299-307. PubMed ID: 19095866
[TBL] [Abstract][Full Text] [Related]
11. Chemical and biological investigation of N-hydroxy-valdecoxib: An active metabolite of valdecoxib.
Erdélyi P; Fodor T; Varga AK; Czugler M; Gere A; Fischer J
Bioorg Med Chem; 2008 May; 16(9):5322-30. PubMed ID: 18353655
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous Determination of Parecoxib and Its Metabolite Valdecoxib Concentrations in Beagle Plasma by UPLC-MS/MS and Application for Pharmacokinetics Study.
Li SL; Zhu YL; Zhu CY; Li SB; Li ZH; Qiu XJ
Drug Des Devel Ther; 2020; 14():1117-1125. PubMed ID: 32214797
[TBL] [Abstract][Full Text] [Related]
13. Constitutive cyclo-oxygenase-2 does not contribute to the development of human visceral pain hypersensitivity.
Willert RP; Delaney C; Hobson AR; Thompson DG; Woolf CJ; Aziz Q
Eur J Pain; 2006 Aug; 10(6):487-94. PubMed ID: 16122956
[TBL] [Abstract][Full Text] [Related]
14. Plasma and CNS concentrations of Gaboxadol in rats following subcutaneous administration.
Cremers T; Ebert B
Eur J Pharmacol; 2007 May; 562(1-2):47-52. PubMed ID: 17362924
[TBL] [Abstract][Full Text] [Related]
15. Biotransformation of valdecoxib by microbial cultures.
Keshetti S; Ciddi V
J Microbiol Biotechnol; 2010 Apr; 20(4):809-16. PubMed ID: 20467258
[TBL] [Abstract][Full Text] [Related]
16. Simultaneous detection and quantification of parecoxib and valdecoxib in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology.
Saccomanni G; Giorgi M; Del Carlo S; Manera C; Saba A; Macchia M
Anal Bioanal Chem; 2011 Sep; 401(5):1677-84. PubMed ID: 21769548
[TBL] [Abstract][Full Text] [Related]
17. Central nervous system distribution kinetics of indinavir in rats.
Hamidi M
J Pharm Pharmacol; 2007 Aug; 59(8):1077-85. PubMed ID: 17725849
[TBL] [Abstract][Full Text] [Related]
18. A liquid chromatography-mass spectrometry method for the quantification of both etoricoxib and valdecoxib in human plasma.
Werner U; Werner D; Hinz B; Lambrecht C; Brune K
Biomed Chromatogr; 2005 Mar; 19(2):113-8. PubMed ID: 15473012
[TBL] [Abstract][Full Text] [Related]
19. Lack of correlation between the central anti-nociceptive and peripheral anti-inflammatory effects of selective COX-2 inhibitor parecoxib.
Urdaneta A; Siso A; Urdaneta B; Cardenas R; Quintero L; Avila R; Suarez-Roca H
Brain Res Bull; 2009 Aug; 80(1-2):56-61. PubMed ID: 19463915
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and metabolism of a COX-2 inhibitor, valdecoxib, in mice.
Zhang JY; Yuan JJ; Wang YF; Bible RH; Breau AP
Drug Metab Dispos; 2003 Apr; 31(4):491-501. PubMed ID: 12642477
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
